Ontology highlight
ABSTRACT:
SUBMITTER: Lai Y
PROVIDER: S-EPMC6848262 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Frontiers in oncology 20191105
As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sora ...[more]